Statins are a potential means of preventing venous thromboembolism (VTE), complementing traditional anticoagulants, without concomitant bleeding-related complications. The purpose of this study was to compare the prothrombotic activity of different classes of lipid-lowering drugs in an active comparative study and determine whether there is a link between the use of statins, fibrates/niacin and procoagulant factors.Currently, taking statins is associated with lower plasma FXA levels than taking fibrates/niacin. The effect on blood clotting factors may partly explain the benefits of statin therapy in the primary and secondary prevention of VTE.

Study group characteristics, Pathogenetic markers, Anticoagulation therapy, Anticoagulation modes, Coagulation parameters, Hemostasis markers, Thrombotic risk.

Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3–14.

Pastori D, Farcomeni A, Milanese A, Del Sole F, Menichelli D, Hiatt WR, et al. Statins and major adverse limb events in patients with peripheral artery disease: a systematic review and meta-analysis. Thromb Haemost. 2020; 120(5):866–75.

Braekkan SK, Caram-Deelder C, Siegerink B, van Hylckama VA, le Cessie S, Rosendaal FR, et al. Statin use and risk of recurrent venous thrombosis: results from the MEGA follow-up study. Res Pract Thromb Haemostasis. 2017;1(1):112–9.

Kunutsor SK, Seidu S, Khunti K. Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies. Eur Heart J. 2017;38(20):1608–12.

Li L, Zhang P, Tian JH, Yang K. Statins for primary prevention of venous thromboembolism. Cochrane Database Syst Rev. 2014;12: Cd008203.

Schmidt M, Cannegieter SC, Johannesdottir SA, Dekkers OM, Horvath-Puho E, Sorensen HT. Statin use and venous thromboembolism recurrence: a combined nationwide cohort and nested case-control study. J Thromb Haemostasis. 2014;12(8):1207–15.

Smith NL, Harrington LB, Blondon M, Wiggins KL, Floyd JS, Sitlani CM, et al. The association of statin therapy with the risk of recurrent venous thrombosis. J Thromb Haemostasis. 2016;14(7):1384–92.

Tagalakis V, Eberg M, Kahn S, Azoulay L. Use of statins and reduced risk of recurrence of VTE in an older population. A population-based cohort study. Thromb Haemost. 2016;115(6):1220–8.

Lassila R, Jula A, Pitkaniemi J, Haukka J. The association of statin use with reduced incidence of venous thromboembolism: a population-based cohort study. BMJ Open. 2014;4(11):e005862.

Gaertner S, Cordeanu EM, Nouri S, Mirea C, Stephan D. Statins and prevention of venous thromboembolism: myth or reality? Arch Cardiovasc Dis. 2016;109(3):216–22.

Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21(11): 1712–9.

Pignatelli P, Carnevale R, Pastori D, Cangemi R, Napoleone L, Bartimoccia S, et al. Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2. Circulation. 2012;126(1):92–103.

Chaffey P, Thompson M, Pai AD, Tafreshi AR, Tafreshi J, Pai RG. Usefulness of statins for prevention of venous thromboembolism. Am J Cardiol. 2018; 121(11):1436–40.

Adams NB, Lutsey PL, Folsom AR, Herrington DH, Sibley CT, Zakai NA, et al. Statin therapy and levels of hemostatic factors in a healthy population: the multi-ethnic study of atherosclerosis. J Thromb Haemostasis. 2013;11(6): 1078–84.

Bianconi V, Sahebkar A, Banach M, Pirro M. Statins, haemostatic factors and thrombotic risk. Curr Opin Cardiol. 2017;32(4):460–6.

Oikonomou E, Leopoulou M, Theofilis P, Antonopoulos AS, Siasos G, Latsios G, et al. A link between inflammation and thrombosis in atherosclerotic cardiovascular diseases: clinical and therapeutic implications. Atherosclerosis. 2020;309:16–26.

Biedermann JS, Kruip M, van der Meer FJ, Rosendaal FR, Leebeek FWG, Cannegieter SC, et al. Rosuvastatin use improves measures of coagulation in patients with venous thrombosis. Eur Heart J. 2018;39(19):1740–7.

Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ (Clinical research ed). 2003;326(7404):1423.

Sipahi I, Nicholls SJ, Tuzcu EM, Nissen SE. Coronary atherosclerosis can regress with very intensive statin therapy. Cleve Clin J Med. 2006;73(10): 937–44.

Rahimi K, Bhala N, Kamphuisen P, Emberson J, Biere-Rafi S, Krane V, et al. Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Med. 2012;9(9):e1001310